Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Related Clinical Trial
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Immune Responses to COVID-19 Vaccination in Lymphoma Patients Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Covid-19 Vaccine Responsiveness in MM and Waldenstrom Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Bendamustine, Rituximab and Acalabrutinib in Waldenstrom’s Macroglobulinemia CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom’s Macroglobulinemia A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Copanlisib and Nivolumab in Treating Participants With Richter’s Transformation or Transformed Indolent Non-Hodgkin’s Lymphoma Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Allo HSCT Using RIC for Hematological Diseases Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Safety and Tolerability of HSC835 in Patients With Hematological Malignancies T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin’s Lymphoma or T-cell Lymphoma Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma Study of MLN8237 in Participants With Advanced Hematological Malignancies 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin’s or Non-Hodgkin’s Lymphoma MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders FAU in Treating Patients With Advanced Solid Tumors or Lymphoma Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant A Long-term Extension Study of PCI-32765 (Ibrutinib) Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies The Master Registry of Oncology Outcomes Associated With Testing and Treatment Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Nonmyeloablative Allogeneic Transplant Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma A Phase II Study of Doxycycline in Relapsed NHL Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin’s Lymphoma Imexon for Relapsed Follicular and Aggressive Lymphomas Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators’ Expression in Allogeneic SCT Using FluBuATG Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas Trial of AVN-944 in Patients With Advanced Hematologic Malignancies A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Rifaximin in Patients With Monoclonal Gammopathy Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma B-Cell Hematologic Malignancy Vaccination Registry Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm’s Macroglobulinemia BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) A Study of ARQ 531 in Patients With Selected Hematologic Malignancies Ibrutinib + Venetoclax in Untreated WM Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma A Phase II Study of Carfilzomib in Relapsed Waldenström’s Macroglobulinemia (WM) IST-CAR-531 Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin’s Lymphoma Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors Bortezomib and Rituximab for Patients With Waldenstrom’s Macroglobulinemia Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Everolimus (RAD001) in Primary Therapy of Waldenstrom’s Macroglobulinemia Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom’s Macroglobulinemia Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom’s Macroglobulinemia Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom’s Macroglobulinemia APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom’s Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström’s Macroglobulinemia (WM) A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom’s Macroglobulinemia (WM) A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström’s Macroglobulinemia Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström’s Macroglobulinemia Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401 DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom’s Macroglobulinemia Patients Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström’s Macroglobulinemia (WM) Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström’s Macroglobulinemia and in IgM-MGUS Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia Perifosine in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia Randomised Trial in Waldenstrom’s Macroglobulinaemia A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom’s Macroglobulinemia (WM) Pomalidomide, Dexamethasone and Rituximab in Waldenstrom’s Macroglobulinemia Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Study of Epratuzumab (hLL2) in Patients With Waldenstrom’s Macroglobulinemia A Study for Patients That Have Been Previously Been Treated in Waldenstrom’s Macroglobulinemia or Multiple Myeloma Ibrutinib With Rituximab in Adults With Waldenström’s Macroglobulinemia Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia Simvastatin in Waldenstrom’s Macroglobulinemia Ibrutinib (PCI-32765) in Waldenstrom’s Macroglobulinemia Carfilzomib, Rituximab and Dexamethasone in Waldenstrom’s Macroglobulinemia Thalidomide and Rituximab in Waldenstrom’s Macroglobulinemia Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia’s Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom’s Macroglobulinemia Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom’s Macroglobulinemia Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom’s Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia A Phase II Trial of Ofatumumab in Subjects With Waldenstrom’s Macroglobulinemia Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia Expression of Ku70/XRCC6 in Waldenström’s Macroglobulinemia Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom’s Macroglobulinemia Study of VTD in Waldenstrom’s Macroglobulinemia Dasatinib In Waldenström Macroglobulinemia The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia Combination Bortezomib and Rituximab in Patients With Waldenstrom’s Macroglobulinemia R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom’s Macroglobulinemia Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom’s Macroglobulinemia Efficacy of First Line B-RI for Treatment Naive Waldenström’s Macroglobulinemia Sildenafil Citrate in Waldenstrom’s Macroglobulinemia Bortezomib (Velcade) in Waldenstrom’s Macroglobulinemia Phase II Study of Campath-1H Antibody to Treat Waldenstrom’s Macroglobulinemia

Brief Title

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Official Title

Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)

Brief Summary

      This phase II trial is studying how well umbilical cord blood transplant from a donor works
      in treating patients with hematological cancer. Giving chemotherapy and total-body
      irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of
      cancer and abnormal cells and helps stop the patient's immune system from rejecting the
      donor's stem cells. When the healthy stem cells from an unrelated donor, that do not exactly
      match the patient's blood, are infused into the patient they may help the patient's bone
      marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
      transplanted cells from a donor can make an immune response against the body's normal cells
      (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and
      after transplant may stop this from happening.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. Estimate probability of one year survival.

      II. Demonstrate equivalent or improved engraftment rates with a non-anti-thymocyte globulin
      (ATG) based conditioning regimen. Patients will be considered graft failure/rejections
      provided they meet any of the criteria listed below:

        -  Absence of 3 consecutive days with neutrophils >= 500/ul combined with host cluster of
           differentiation (CD)3 peripheral blood chimerism >= 50% at day 42

        -  Absence of 3 consecutive days with neutrophils >= 500/ul under any circumstances at day
           55

        -  Death after day 28 with neutrophil count < 100/ul without any evidence of engraftment (<
           5% donor CD3)

        -  Primary autologous count recovery with < 5% donor CD3 peripheral blood chimerism at
           count recovery and without relapse

      SECONDARY OBJECTIVES:

      I. Six month non-relapse mortality.

      II. Overall incidence of graft failure/rejection. Patients will be considered graft
      failure/rejections provided they meet any of the criteria listed below:

        -  Absence of 3 consecutive days with neutrophils >= 500/ul combined with host CD3
           peripheral blood chimerism >= 50% at day 42

        -  Absence of 3 consecutive days with neutrophils >= 500/ul under any circumstances at day
           55

        -  Death after day 28 with neutrophil count < 100/ul without any evidence of engraftment (<
           5% donor CD3)

        -  Primary autologous count recovery with < 5% donor CD3 peripheral blood chimerism at
           count recovery and without relapse

      III. Kinetics of chimeric reconstitution.

      IV. Incidence of neutrophil engraftment by day 42.

      V. Incidence of platelet engraftment by six months.

      VI. Incidence of grade II-IV and III-IV acute graft-versus-host disease (GvHD) at day 100.

      VII. Incidence of one year chronic GvHD.

      VIII. Incidence of clinically significant infections at 6 months, 1 year, 2 years.

      IX. Probability of one and two year survival.

      X. Incidence of one and two year relapse or disease progression.

      XI. Fred Hutchinson Cancer Research Center (FHCRC) patients: Kinetics of immune
      reconstitution, with both functional and quantitative assays.

      XII. FHCRC patients: Examination of possible immunologic factors leading to emergence of a
      dominant unit.

      OUTLINE:

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) over 1 hour
      on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower
      dose of total-body irradiation (TBI) on day -1.

      UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day
      0.

      IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on
      days -3 to +180 and mycophenolate mofetil IV or orally (PO) every 8 hours on days 0 to +96.

      After completion of study treatment, patients are followed periodically for up to 2 years.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Overall Survival

Secondary Outcome

 Median Time to ANC > 500

Condition

Acute Lymphoblastic Leukemia

Intervention

Allogeneic Hematopoietic Stem Cell Transplantation

Study Arms / Comparison Groups

 Treatment (chemotherapy, transplant)
Description:  CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.
UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.
IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

73

Start Date

June 25, 2008

Completion Date

July 31, 2018

Primary Completion Date

July 31, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients > 70 may be considered if performance status > 80% or Eastern Cooperative
             Oncology Group (ECOG) =< 1 and comorbidity score < 3; these patients must be discussed
             with the principal investigator (PI), Rachel Salit prior to enrollment

          -  Adequate cardiac function defined as absence of decompensated congestive heart
             failure, or uncontrolled arrhythmia and:

               -  Left ventricular ejection fraction >= 35% or

               -  Fractional shortening > 22%

          -  Adequate pulmonary function defined as diffusion capacity of carbon monoxide (DLCO) >
             30% predicted, and absence of oxygen (O2) requirements

          -  Adequate hepatic function; patients with clinical or laboratory evidence of liver
             disease will be evaluated for the cause of liver disease, its clinical severity in
             terms of liver function, histology, and the degree of portal hypertension; patients
             with fulminant liver failure, cirrhosis with evidence of portal hypertension or
             bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding
             esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic
             dysfunction evidenced by prolongation of the prothrombin time, ascites related to
             portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral
             hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will
             be excluded

          -  Adequate renal function defined as creatinine =< 2.0 mg/dl (adults) or creatinine
             clearance > 40 ml/min (pediatrics)

          -  All adults with a creatinine > 1.2 or a history of renal dysfunction must have
             estimated creatinine clearance > 40 ml/min

          -  Performance status score: Karnofsky (for adults) >= 60 or ECOG 0-2; Lansky (for
             children) score >= 50

          -  If recent mold infection, e.g., Aspergillus, must be cleared by infectious disease

          -  Second hematopoietic cell transplant: Must be >= 3 months after prior myeloablative
             transplant

          -  Patients who have received < 2 cycles of multiagent chemotherapy and patients who have
             received no multiagent chemotherapy within the 3 months previous to umbilical cord
             blood transplant (UCBT) as well as patients experiencing graft failure following
             previous allogeneic transplant

          -  Acute myeloid leukemia/acute lymphoblastic leukemia, including biphenotypic acute
             leukemia or mixed-lineage leukemia: Must have < 5% morphologic marrow blasts in an
             evaluable marrow (> 25% of normal cellularity for age) collected less than one month
             prior to start of conditioning; patients persistently aplastic for greater than one
             month since completing last chemotherapy are also eligible with the approval of the PI
             or designee

          -  Chronic myelogenous leukemia: All types, except refractory blast crisis; chronic phase
             patients must have failed or been intolerant to Gleevec or other tyrosine kinase
             inhibitors; at time of transplant, patients must have < 5% blasts in an evaluable
             marrow (> 25% of normal cellularity for age) by morphology within the bone marrow

          -  Myelodysplastic syndrome (MDS): Any subtype; morphologic blasts must be less than 5%
             in an evaluable marrow (> 25% of normal cellularity for age); if blasts are 5% or
             more, patient requires induction chemotherapy pre-transplant to reduce blast count to
             less than 5%; patients who have a hypocellular marrow in the absence of excess blasts
             that is related to the underlying disease or as a result of treatment for MDS may also
             be eligible with the approval of the PI or designee

          -  Large-cell lymphoma and aggressive T-cell lymphoma: With chemotherapy sensitive
             disease that has failed autologous transplant or patients who are ineligible for an
             autologous transplant; chemotherapy sensitive disease is defined as >= 50% reduction
             in the size of the tumor with the chemotherapy regimen immediately preceding
             transplant

          -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Must be refractory
             to fludarabine (fludarabine phosphate) or fail to have a complete or partial response
             after therapy with a regimen containing fludarabine (or another nucleoside analog,
             e.g. cladribine [2-CDA], pentostatin) or experience disease relapse within 12 months
             after completing therapy with a regimen containing fludarabine (or another nucleoside
             analog)

          -  Hodgkin disease: Must have received and failed frontline therapy

          -  Follicular lymphoma, marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma,
             mantle-cell lymphoma, and indolent T-cell lymphomas: Must have progressed with the
             most recent remission duration being < 6 months; patients with bulky disease should be
             considered for debulking chemotherapy before transplant; patients with refractory
             disease are eligible, unless they have bulky disease and an estimated tumor doubling
             time of less than one month

          -  Multiple myeloma: Must have received prior chemotherapy; consolidation of chemotherapy
             by autografting prior to nonmyeloablative hematopoietic cell transplant (HCT) is
             permitted

          -  Myeloproliferative syndromes

          -  DONOR: Cord blood (CB) donor selection will be based on institutional guidelines and
             in general should be selected to optimize both human leukocyte antigen (HLA) match and
             cell dose; additionally, CB grafts shall consist of one or two CB donors based on, but
             not exclusively determined by, cell dose (total nucleated cell [TNC]/kg and CD34/kg),
             HLA matching and disease status and indication for transplant; attending preference
             will be allowed for single versus double unit as well as the degree of mismatching
             based on patient specific factors, as long as the following minimum criteria are met:

               -  HLA matching

                    -  Minimum requirement: The CB graft(s) must be matched at a minimum at 4/6
                       HLA-A, B, DRB1 loci with the recipient. Therefore 0-2 mismatches at the A or
                       B or DRB1 loci based on intermediate resolution A, B antigen and DRB1 allele
                       typing for determination of HLA-match is allowed

                    -  HLA-matching determined by high-resolution typing is allowed per
                       institutional guidelines as long as the minimum criteria are met

               -  Selection of two CB units is mandatory when a single cord blood unit does not
                  meet the following criteria:

                    -  Match grade 6/6; TNC Dose >= 2.5 x 10^7/kg

                    -  Match grade 5/6 or 4/6; TNC dose >= 4.0 (+/- 0.5) x 10^7/kg

               -  If two CB units are used, the total cell dose of the combined units must be at
                  least 3.0 x 10^7 TNC per kilogram recipient weight based on pre-cryopreservation
                  numbers, with each CB unit containing a MINIMUM of 1.5 x 10^7 TNC/kg

               -  The minimum recommended CD34/kg cell dose should be 2 x 10^5 CD34/kg, total dose
                  from a single or combined double

               -  The unmanipulated CB unit(s) will be Food and Drug Administration (FDA) licensed
                  or will be obtained under a separate investigational new drug (IND), such as the
                  National Marrow Donor Program (NMDP) Protocol 10-CBA conducted under BB IND-7555
                  or another IND sponsored by (1) a participating institution or (2) an
                  investigator at FHCRC or one of the participating institutions

               -  FHCRC only: Up to 5% of cord blood product, when ready for infusion, may be
                  withheld for research purposes as long as thresholds for infused TNC dose are
                  met; threshold for double unit transplantation is >= 3.0 x 10^7/kg; these
                  products will be used to conduct studies involving the immunobiology of double
                  cord transplantation and kinetics of engraftment

        Exclusion Criteria:

          -  Patients with an available 5-6/6 HLA-A, B, DRB1 matched sibling donor

          -  Pregnancy or breastfeeding

          -  Evidence of human immunodeficiency virus (HIV) infection or known HIV positive
             serology

          -  Uncontrolled viral or bacterial infection at the time of study enrollment

          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease
             (ID) consult and approval

          -  Active central nervous system malignancy

          -  Patients who have received >= 2 cycles of multiagent chemotherapy within the 3 months
             previous to UCBT; patients who have had previous autologous transplant within 12
             months of UCBT are excluded regardless of history of recent treatment

          -  DONOR: Any cord blood units with < 1.5 x 10^7 total nucleated cells per kilogram
             recipient weight

          -  DONOR: Any cord blood units without the full maternal testing and negative results for
             hepatitis A, B, C, HIV, and human T-lymphotropic virus (HTLV-1) viruses; any
             additional available virology results on the unit itself will be reviewed but are not
             mandated, complete or always available; cord blood units are presumed to be
             cytomegalovirus (CMV) negative regardless of serologic testing due to passive
             transmission of maternal CMV antibodies
      

Gender

All

Ages

N/A - 69 Years

Accepts Healthy Volunteers

No

Contacts

Rachel Salit, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00723099

Organization ID

2239.00

Secondary IDs

NCI-2009-01551

Responsible Party

Sponsor

Study Sponsor

Fred Hutchinson Cancer Research Center

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Rachel Salit, Principal Investigator, Fred Hutch/University of Washington Cancer Consortium


Verification Date

December 2019